Article info

Original research
Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids

Authors

  1. Correspondence to Dr Egle Ramelyte; egle.ramelyte{at}usz.ch
View Full Text

Citation

Burri E, Mangana J, Cheng PF, et al
Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids

Publication history

  • Accepted May 2, 2024
  • First published July 5, 2024.
Online issue publication 
July 05, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.